A Phase 4 interventional study of Alirocumab in Coronary Artery Disease and Thin-cap fIbroatheroma, sponsored by Kobe University. Status unknown at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-11-14.
Sponsored by Kobe University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Coronary Artery Disease by Kobe University — 1 open to participants now, 1 under way, none of them phase 3. Coronary Artery Disease · Kobe University.
Among the 10 studies in Coronary Artery Disease by Kobe University, this one is one of 2 that started in 2017, is one of 5 in phase 4, and was the 5th registered.
4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →1 of the 10 studies in Coronary Artery Disease by Kobe University is open now, in 1 country. Recruiting first, the newest first:
Kobe University · Sites in Japan
Ages 20+
By country, each count listing its studies:
Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 124 across 3,010 interventional studies indexed under Coronary Artery Disease.
Median enrollment 50 across the 7 interventional studies, 72 across the 3 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Kobe University is the lead sponsor of 17 studies on the registry; 1 is open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Coronary Artery Disease by Kobe University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
the purpose of this study is to show that alirocumab with statin therapy have a s tronger stabilizing effect on vulnerable plaque in coronary artery disease than statin alone administration
The investigators investigate to evaluate the efficacy of alirocumab for vulnerable plaque. The investigators enrolled the patient with standard statin therapy who were detected vulnerable plaque by optical coherence tomography, and categorized into two group; the patients with alirocumab and rosuvastatin were categorized alirocumab therapy group, and the patients with rosuvastatin alone were categorized standard statin therapy group. The investigators compare these two group for outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
start with alirocumab 75mg per 2weeks and rosuvastatin 10mg per day
Drug: Alirocumab
start with only rosuvastatin 10mg per day
the administration of Alirocumab by Subcutaneous injection 75mg every 2 weeks plus Rosuvastatin10mg/daily by oral for 9 months
the change in fibrous cap thickness
the absolute change in minimum fibrous-cap thickness between baseline and 36-week follow-up
Time frame: 9 month
the change in fibrous cap thickness
the percent change in minimum fibrous-cap thickness between baseline and 36-week follow-up
Time frame: 9 month
the change in lipid index
absolute change in lipid index between baseline and 36-week follow-up
Time frame: 9 month
the change in lipid index
percentage change in lipid index between baseline and 36-week follow-up
Time frame: 9 month
the change in lipid length,
absolute change in lipid core length between baseline and 36-week follow-up
Time frame: 9 month
the change in lipid length,
percentage change in lipid core length between baseline and 36-week follow-up
Time frame: 9 month
the change in mean lipid arc
absolute change in mean lipid arc between baseline and 36-week follow-up
Time frame: 9 month
the change in mean lipid arc
percentage change in mean lipid arc between baseline and 36-week follow-up
Time frame: 9 month
the change in max lipid arc
absolute change in max lipid arc between baseline and 36-week follow-up
Time frame: 9 month
the change in max lipid arc
percent change in max lipid arc between baseline and 36-week follow-up
Time frame: 9 month
the change in macrophage grade
absolute change in summation of macrophage grade between baseline and 36-week follow-up. macrophage grade defined as an OCT macrophage grading system to semiquantify the bright spots based on axial and circumferential distribution, as follows: grade 0, no macrophage; grade 1, localized macrophage accumulation; grade 2, clustered accumulation \<1 quadrant; grade 3, clustered accumulation \>1 quadrant and ≦3 quadrants; and grade 4, clustered accumulation ≧3
Time frame: 9 month
the change in macrophage grade
percentage change in summation of macrophage grade between baseline and 36-week follow-up. macrophage grade defined as an OCT macrophage grading system to semiquantify the bright spots based on axial and circumferential distribution, as follows: grade 0, no macrophage; grade 1, localized macrophage accumulation; grade 2, clustered accumulation \<1 quadrant; grade 3, clustered accumulation \>1 quadrant and ≦3 quadrants; and grade 4, clustered accumulation ≧3
Time frame: 9 month
the change in minimum lumen area
absolute change in minimum lumen area between baseline and 36-week follow-up
Time frame: 9 month
the change in minimum lumen area
percentage of change in minimum lumen area between baseline and 36-week follow-up
Time frame: 9 month
the number of thin-cap fibroatheroma
change of the number of thin-cap fibroatheroma at 36-week follow-up
Time frame: 9 month
the change in total cholesterol
absolute change in serum level of of total cholesterol between baseline and 36-week follow-up
Time frame: 9 month
the change in total cholesterol
percent change in serum level of of total cholesterol between baseline and 36-week follow-up
Time frame: 9 month
the change in LDL-C
absolute change in serum level of of LDL-C between baseline and 36-week follow-up
Time frame: 9 month
the change in LDL-C
percentage change in serum level of of LDL-C between baseline and 36-week follow-up
Time frame: 9 month
the change in HDL-C
absolute change in serum level of of HDL-C between baseline and 36-week follow-up
Time frame: 9 month
the change in HDL-C
percentage change in serum level of of HDL-C between baseline and 36-week follow-up
Time frame: 9 month
the change in non-HDL-C
absolute change in serum level of of non-HDL-C between baseline and 36-week follow-up
Time frame: 9 month
the change in non-HDL-C
percentage change in serum level of of non-HDL-C between baseline and 36-week follow-up
Time frame: 9 month
the change in apolipoprotein B
absolute change in serum level of of apolipoprotein B between baseline and 36-week follow-up
Time frame: 9 month
the change in apolipoprotein B
percentage change in serum level of of apolipoprotein B between baseline and 36-week follow-up
Time frame: 9 month
the change in Lp(a)
absolute change in serum level of of Lp (a) between baseline and 36-week follow-up
Time frame: 9 month
the change in Lp(a)
percentage change in serum level of of Lp (a) between baseline and 36-week follow-up
Time frame: 9 month
the change in hs-CRP
absolute change in serum level of hs-CRP between baseline and 36-week follow-up
Time frame: 9 month
the change in hs-CRP
percentage change in serum level of hs-CRP between baseline and 36-week follow-up
Time frame: 9 month
the change in IL-1β
absolute change in serum level of IL-1β between baseline and 36-week follow-up
Time frame: 9 month
the change in IL-1β
percentage change in serum level of IL-1β between baseline and 36-week follow-up
Time frame: 9 month
the change in IL-6
absolute change in serum level of IL-6 between baseline and 36-week follow-up
Time frame: 9 month
the change in IL-6
percentage change in serum level of IL-6 between baseline and 36-week follow-up
Time frame: 9 month
the change in TNF-α
absolute change in serum level of TNF-α between baseline and 36-week follow-up
Time frame: 9 month
the change in TNF-α
percentage change in serum level of TNF-α between baseline and 36-week follow-up
Time frame: 9 month
the change in MCP-1
absolute change in serum level of MCP-1 between baseline and 36-week follow-up
Time frame: 9 month
the change in MCP-1
percentage change in serum level of MCP-1 between baseline and 36-week follow-up
Time frame: 9 month
the change in MMP-2
absolute change in serum level ofMMP-2 between baseline and 36-week follow-up
Time frame: 9 month
the change in MMP-2
percentage change in serum level ofMMP-2 between baseline and 36-week follow-up
Time frame: 9 month
the change in MMP-9
absolute change in serum level of MMP-9 between baseline and 36-week follow-up
Time frame: 9 month
the change in MMP-9
percentage change in serum level of MMP-9 between baseline and 36-week follow-up
Time frame: 9 month
the change in VCAM-1
absolute change in serum level of VCAM-1between baseline and 36-week follow-up
Time frame: 9 month
the change in VCAM-1
percentage change in serum level of VCAM-1 between baseline and 36-week follow-up
Time frame: 9 month
the change in ICAM-1
absolute change in serum level of ICAM-1 between baseline and 36-week follow-up
Time frame: 9 month
the change in ICAM-1
percentage change in serum level of ICAM-1 between baseline and 36-week follow-up
Time frame: 9 month
the change in free PCSK9
absolute change in serum level of free PCSK9 between baseline and 36-week follow-up
Time frame: 9 month
the change in free PCSK9
percentage change in serum level of free PCSK9 between baseline and 36-week follow-up
Time frame: 9 month
Started Aug 2017 (actual). Primary completion is estimated for Sep 2020, 37 months after the start.
Of 193 phase 4 interventional studies under Coronary Artery Disease, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 58. This study's planned 37 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alirocumab
Kobe University